Olivier Nicolas
Overview
Explore the profile of Olivier Nicolas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
384
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zimmerman B, Dakin L, Fortier A, Nanou E, Blasio A, Mann J, et al.
Nat Commun
. 2025 Jan;
16(1):167.
PMID: 39747090
Chronic kidney disease affects ~10% of people worldwide and there are no disease modifying therapeutics that address the underlying cause of any form of kidney disease. Genome wide association studies...
2.
Alidjinou E, Pomorski Q, Bauvais M, Dupont A, Grenouillet F, Labalette M, et al.
Ann Biol Clin (Paris)
. 2024 Apr;
82(1):43-57.
PMID: 38638018
In France, both students from medicine and pharmacy background can have access to the residency in laboratory medicine (LM). The current curriculum of LM residency includes an early choice of...
3.
Nicolas O, Moliner P, Soubayrol P, Vitse O, Roy S, Cabanis M, et al.
Clin Drug Investig
. 2023 Aug;
43(8):653-665.
PMID: 37642857
Background And Objective: Tolebrutinib is a covalent inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are thought to be major drivers...
4.
Bubenik M, Mader P, Mochirian P, Vallee F, Clark J, Truchon J, et al.
J Med Chem
. 2022 Sep;
65(19):13198-13215.
PMID: 36126059
DNA polymerase theta (Polθ) is an attractive synthetic lethal target for drug discovery, predicted to be efficacious against breast and ovarian cancers harboring BRCA-mutant alleles. Here, we describe our hit-to-lead...
5.
Gallo D, Young J, Fourtounis J, Martino G, Alvarez-Quilon A, Bernier C, et al.
Nature
. 2022 Apr;
604(7907):749-756.
PMID: 35444283
Amplification of the CCNE1 locus on chromosome 19q12 is prevalent in multiple tumour types, particularly in high-grade serous ovarian cancer, uterine tumours and gastro-oesophageal cancers, where high cyclin E levels...
6.
Ahmad A, Pepin X, Aarons L, Wang Y, Darwich A, Wood J, et al.
Eur J Pharm Biopharm
. 2020 Aug;
156:50-63.
PMID: 32805361
Oral drug absorption is a complex process depending on many factors, including the physicochemical properties of the drug, formulation characteristics and their interplay with gastrointestinal physiology and biology. Physiological-based pharmacokinetic...
7.
Li P, Dorsch W, Lauffer D, Bilimoria D, Chauret N, Court J, et al.
ACS Med Chem Lett
. 2017 Feb;
8(2):251-255.
PMID: 28197321
Lomibuvir () is a non-nucleoside, allosteric inhibitor of the hepatitis C virus NS5B polymerase with demonstrated clinical efficacy. Further development efforts within this class of inhibitor focused on improving the...
8.
Margolskee A, Darwich A, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, et al.
Eur J Pharm Sci
. 2016 Nov;
96:610-625.
PMID: 27816631
Orally administered drugs are subject to a number of barriers impacting bioavailability (F), causing challenges during drug and formulation development. Physiologically-based pharmacokinetic (PBPK) modelling can help during drug and formulation...
9.
Darwich A, Margolskee A, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, et al.
Eur J Pharm Sci
. 2016 Oct;
96:626-642.
PMID: 27693299
Three Physiologically Based Pharmacokinetic software packages (GI-Sim, Simcyp® Simulator, and GastroPlus™) were evaluated as part of the Innovative Medicine Initiative Oral Biopharmaceutics Tools project (OrBiTo) during a blinded "bottom-up" anticipation...
10.
Court J, Poisson C, Ardzinski A, Bilimoria D, Chan L, Chandupatla K, et al.
J Med Chem
. 2016 Jul;
59(13):6293-302.
PMID: 27366941
The hepatitis C viral proteins NS3/4A protease, NS5B polymerase, and NS5A are clinically validated targets for direct-acting antiviral therapies. The NS5B polymerase may be inhibited directly through the action of...